昆仙胶囊联合缬沙坦治疗糖尿病肾病Ⅳ期蛋白尿的临床效果  

Clinical effect of Kunxian Capsules combined with Valsartan in the treatment of diabetic nephropathy stage Ⅳ proteinuria

作　　者：王慧敏 吴毅伟 陈祉娴 WANG Huimin;WU Yiwei;CHEN Zhixian(Department of Nephropathy,Tangshan Hospital of Traditional Chinese Medicine,Hebei Province,Tangshan 063000,China;Department of General Surgery,Tangshan Hospital of Traditional Chinese Medicine,Hebei Province,Tangshan 063000,China;School of Medicine,Ji'nan University,Guangdong Province,Guangzhou 510630,China)

机构地区：[1]河北省唐山市中医医院肾病科,河北唐山063000 [2]河北省唐山市中医医院普外科,河北唐山063000 [3]广东省广州市暨南大学医学院,广东广州510630

出　　处：《中国医药导报》2020年第16期156-159,共4页China Medical Herald

基　　金：河北省中医药管理局科研计划项目(2018323)。

摘　　要：目的 探讨昆仙胶囊联合缬沙坦治疗糖尿病肾病Ⅳ期患者蛋白尿的临床效果.方法 选取2018年1月~2019年1月河北省唐山市中医医院住院的糖尿病肾病Ⅳ期患者61例,按照随机数字表法将其分为对照组和观察组.对照组30例予缬沙坦治疗,观察组31例在对照组基础上加用昆仙胶囊治疗.两组患者的治疗疗程为3个月.观察两组患者治疗前后24 h尿蛋白定量,肾功能指标[血尿素氮(BUN)、血肌酐(Scr)、内生肌酐清除率(Ccr)],肝功能指标[血浆白蛋白(Alb)、谷丙转氨酶(ALT)、谷草转氨酶(AST)]及外周血白细胞(WBC)的变化,监测不良反应.结果 治疗前,两组患者24 h尿蛋白定量比较,差异无统计学意义(P>0.05).治疗后,两组患者24 h尿蛋白定量均较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05或P<0.01).两组患者治疗前后组内、组间BUN、Scr、Ccr、Alb、ALT、AST、WBC水平比较,差异无统计学意义(P>0.05).未发现有严重副作用而需要停药者.结论 昆仙胶囊联合缬沙坦治疗糖尿病肾病Ⅳ期临床效果确切,可有效降低糖尿病肾病患者蛋白尿水平,从而能更好地保护肾功能,其安全性好,值得临床推广应用.Objective To explore the clinical effect of Kunxian Capsules combined with Valsartan in the treatment of diabetic nephropathy stageⅣproteinuria.Methods Sixty-one patients with diabetic nephropathy stageⅣadmitted to Tangshan Hospital of Traditional Chinese Medicine,Hebei Province from January 2018 to January 2019 were selected.According to the random number table method,they were divided into the control group and the observation group.Thirty patients in the control group were treated with Valsartan,and thirty-one patients in the observation group were treated with Kunxian Capsules on the basis of the control group.The treatment course of the two groups was 3 months.The changes of quantitative comparison of 24-hour urinary protein,renal function index(blood urea nitrogen[BUN],serum creatinine[Scr],endogenous creatinine clearance rate[Ccr]),liver function index(plasma albumin[Alb],alanine aminotransferase[ALT],aspartate aminotransferase[AST])and peripheral blood leukocyte(WBC)of the two groups before and after treatment were observed and the adverse reactions were monitored.Results Before treatment,the quantitative comparison of 24-hour urinary protein between the two groups was not statistically significant difference(P>0.05).After treatment,the quantitative comparison of 24-hour urinary protein in both groups was lower than that before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05 or P<0.01).There were no statistically significant differences in BUN,Scr,Ccr,Alb,ALT,AST and WBC levels between the two groups before and after treatment(P>0.05).No serious side effects were found that required drug withdrawal.Conclusion Kunxian Capsules combined with Valsartan is effective in the treatment of diabetic nephropathy stageⅣ,which can effectively reduce the level of patients with diabetic nephropathy proteinuria,so as to better protect renal function,and its safety is good,worthy of clinical promotion and application.

关 键 词：昆仙胶囊 缬沙坦 糖尿病肾病 蛋白尿 

分 类 号：R587.2[医药卫生—内分泌]